Please use this identifier to cite or link to this item:
http://hdl.handle.net/11054/31
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Hurley, James C. | * |
dc.date.accessioned | 2012-10-14T22:56:27Z | en |
dc.date.available | 2012-10-14T22:56:27Z | en |
dc.date.issued | 2008 | en |
dc.identifier.govdoc | 00018 | en |
dc.identifier.issn | 0305-7453 | en |
dc.identifier.uri | http://hdl.handle.net/11054/31 | en |
dc.description.abstract | BACKGROUND: The ventilator-associated pneumonia incident proportion (VAP-IP) is highly variable among control groups of studies of methods for its prevention. The objective here is to develop and validate a literature-derived benchmark against which these groups can be profiled. METHODS: A literature search yielded 95 cohort groups and control and intervention groups of 150 studies of either non-antimicrobial or antimicrobial methods of VAP prevention. The 95 cohort groups comprise a benchmark set (30 groups), from which the reference funnel plot (RFP) was derived, and a search set (65 groups), against which the benchmark was validated. The VAP-IP data of the benchmark set were found in five published systematic reviews, whereas the VAP-IP data of the search set were abstracted directly from the literature. FINDINGS: Among the 95 cohort groups, the VAP-IP of groups with size >399 was significantly lower than the VAP-IP of smaller groups. Compared with the RFP, 15 of 51 (29%) control groups from studies of antimicrobial methods of VAP prevention with concurrent design were high outlier versus 2 of 110 (2%) control groups from other types of study design (P < 0.001). There were only 22 (14%) outlier groups, all low outlier, among the 162 intervention groups. CONCLUSIONS: Study design factors such as concurrency and study size have potentially greater influence on the VAP-IP than do the VAP prevention methods under study. The outlier status of control groups were inapparent in the individual studies and the meta-analyses and yet would have confounded the estimates of treatment effect. | en |
dc.description.provenance | Approved for entry into archive by Gemma Siemensma (gemmas@bhs.org.au) on 2012-10-14T22:56:27Z (GMT) No. of bitstreams: 0 | en |
dc.description.provenance | Submitted by Gemma Siemensma (gemmas@bhs.org.au) on 2012-10-14T22:56:06ZNo. of bitstreams: 0 | en |
dc.description.provenance | Made available in DSpace on 2012-10-14T22:56:27Z (GMT). No. of bitstreams: 0 Previous issue date: 2008 | en |
dc.publisher | Academic Press | en |
dc.title | Profound effect of study design factors on ventilator-associated pneumonia incidence of prevention studies: benchmarking the literature experience. | en |
dc.type | Journal Article | en |
dc.type.specified | Article | en |
dc.bibliographicCitation.title | The Journal of Antimicrobial Chemotherapy | en |
dc.bibliographicCitation.volume | 61 | en |
dc.bibliographicCitation.issue | 5 | en |
dc.bibliographicCitation.stpage | 1154 | en |
dc.bibliographicCitation.endpage | 1161 | en |
dc.publisher.place | London | en |
dc.subject.healththesaurus | RESEARCH SUPPORT - NON U.S GOVERNMENT | en |
dc.subject.healththesaurus | ANTI BACTERIAL-AGENTS - THERAPEUTIC USE | en |
dc.subject.healththesaurus | BENCHMARKING | en |
dc.subject.healththesaurus | CLINICAL TRIALS AS TOPIC | en |
dc.subject.healththesaurus | HUMANS | en |
dc.subject.healththesaurus | INCIDENCE | en |
dc.subject.healththesaurus | VENTILATOR ASSOCIATED PNEUMONIA | en |
dc.subject.healththesaurus | RESEARCH DESIGN | en |
dc.subject.healththesaurus | RESPIRATION - ARTIFICIAL - ADVERSE EFFECTS | en |
dc.date.issuedbrowse | 2008-01-01 | en |
Appears in Collections: | Research Output |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.